Clinical Context
Dexamethasone is widely used perioperatively for prevention of postoperative nausea and vomiting (PONV), reduction of inflammation and edema, and potential analgesic benefits. Standard PONV prophylaxis protocols often include dexamethasone 4-8 mg as a single intraoperative dose. The drug is highly effective—reducing PONV by approximately 25%—and has become near-ubiquitous in anesthetic practice for procedures with moderate-to-high PONV risk.
However, glucocorticoids are known to raise blood glucose through multiple mechanisms: they increase hepatic gluconeogenesis, induce insulin resistance, and impair peripheral glucose uptake. For patients with diabetes, there has been longstanding concern that even a single dose of dexamethasone might cause clinically significant hyperglycemia, potentially worsening surgical outcomes (as perioperative hyperglycemia is associated with increased infection rates, impaired wound healing, and longer hospital stays).
This concern has led some practitioners to withhold dexamethasone from diabetic patients, potentially denying them the benefits of PONV prophylaxis. This randomized controlled trial directly addresses whether a single intraoperative dexamethasone dose causes clinically significant hyperglycemia in well-controlled diabetic (and non-diabetic) surgical patients.
Study Summary (PICO Framework)
Summary:
In well-controlled diabetic and non-diabetic patients undergoing surgery, a single intraoperative dose of dexamethasone did not cause clinically significant hyperglycemia (>180 mg/dL) while effectively preventing PONV compared to placebo, with only transient, modest glucose elevation that resolved without intervention.
| PICO | Description |
|---|---|
| Population | Well-controlled diabetic and non-diabetic adults undergoing surgery. |
| Intervention | Single intraoperative dose of dexamethasone (for PONV prophylaxis). |
| Comparison | Placebo during surgery. |
| Outcome | Blood glucose remained <180 mg/dL. Transient elevation occurred but was not clinically significant. Effective PONV prophylaxis maintained. |
Clinical Pearls
1. The 180 mg/dL threshold is clinically meaningful. Perioperative glucose targets typically aim for <180 mg/dL (10 mmol/L) based on evidence that tighter control increases hypoglycemia risk without clear benefit, while levels consistently above 180 mg/dL are associated with adverse outcomes. That dexamethasone didn't push glucose above this threshold in well-controlled diabetics suggests the hyperglycemic effect is modest and manageable.
2. “Well-controlled” diabetes is the key qualifier. The study population had well-controlled diabetes (presumably HbA1c 9% or baseline glucose >200 mg/dL, extra caution and monitoring may still be warranted.
3. Transient elevation doesn’t require treatment if it resolves. Dexamethasone did cause glucose elevation—just not to clinically significant levels. This transient hyperglycemia typically peaks 6-12 hours post-dose and resolves within 24 hours. For a single PONV prophylaxis dose, this time course overlaps with the immediate postoperative period when patients are monitored anyway. Brief elevations that resolve without intervention don’t require glucose-lowering treatment.
4. Withholding dexamethasone may cause more harm than the glucose effect. PONV is not trivial—it causes significant patient distress, can lead to aspiration, dehiscence of surgical sites, and prolongs recovery. Denying effective prophylaxis to diabetic patients based on theoretical glucose concerns may do more harm than the modest, transient hyperglycemia that actually occurs. This study supports a more rational benefit-risk analysis.
Practical Application
Don’t routinely withhold dexamethasone from diabetic patients: For patients with well-controlled diabetes undergoing procedures where dexamethasone is indicated for PONV prophylaxis, this evidence supports proceeding with standard dosing. The benefits of PONV prevention likely outweigh the minimal glucose impact. Communicate this approach to surgical and anesthesia colleagues who may have outdated concerns.
Monitor glucose as part of standard perioperative care: Diabetic patients undergoing surgery should have glucose monitored regardless of dexamethasone use—surgery itself is a stress that elevates glucose. Checking glucose in recovery and on the ward allows detection of hyperglycemia from any cause. Having dexamethasone on board doesn’t substantially change the monitoring approach.
Consider patient-specific factors for poorly controlled diabetes: For patients with HbA1c >9%, fasting glucose >200 mg/dL, or history of severe hyperglycemic episodes, the calculus may differ. These patients may benefit from additional glucose monitoring, lower dexamethasone doses (4 mg rather than 8 mg), or alternative PONV prophylaxis (ondansetron, aprepitant). Individualize based on diabetes severity and PONV risk.
Educate patients about expectations: Diabetic patients may notice higher glucose readings in the day after surgery. Explain that this is expected (from surgical stress, fasting, and potentially dexamethasone), typically resolves quickly, and usually doesn’t require diabetes medication adjustment. Prevent unnecessary patient anxiety about transient postoperative hyperglycemia.
How This Study Fits Into the Broader Evidence
Multiple studies have examined dexamethasone and perioperative glucose, with generally reassuring findings for single-dose use. A meta-analysis found that perioperative dexamethasone increases glucose by approximately 20-40 mg/dL on average—a real but modest effect. Most patients, including those with well-controlled diabetes, remain below clinically significant thresholds.
Enhanced Recovery After Surgery (ERAS) protocols increasingly include dexamethasone for its anti-inflammatory, antiemetic, and potentially analgesic benefits. The ERAS Society’s guidelines generally support dexamethasone use in diabetic patients with appropriate monitoring, reflecting the evolving evidence that benefits outweigh risks.
For patients requiring multiple dexamethasone doses (such as in oncologic regimens or prolonged surgeries), cumulative hyperglycemic effects become more pronounced and require more active glucose management. The current study specifically addresses single-dose perioperative use.
Limitations to Consider
The dexamethasone dose and surgery types aren’t detailed. “Well-controlled” diabetes criteria aren’t specified, limiting generalizability to poorly controlled patients. Follow-up duration (how long glucose was monitored) affects whether delayed hyperglycemia was captured. Comparison of diabetic vs. non-diabetic subgroups would clarify diabetes-specific responses. Sample size determines power to detect modest differences.
Bottom Line
A single intraoperative dexamethasone dose for PONV prophylaxis did not cause clinically significant hyperglycemia (>180 mg/dL) in well-controlled diabetic or non-diabetic surgical patients, while effectively preventing nausea and vomiting. Glucose elevation occurred but was transient and did not require intervention. For patients with well-controlled diabetes, this supports using dexamethasone when indicated without routinely withholding for glucose concerns. Monitor glucose as part of standard perioperative care, and individualize decisions for poorly controlled diabetics.
Source: Nadia Rose, et al. “The Effect of Single Intraoperative Dose of Dexamethasone on the Blood Glucose Concentration in Diabetic and Non-Diabetic Patients: A Double Blinded Randomized Control Study.” Read article here.
